In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
En el estudio, trastuzumab deruxtecan demostró una mejora clínica y estadísticamente significativa, tanto en supervivencia libre de progresión (SLP) como en supervivencia global (SG ...
Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
And that story is still being written. Now, Geyer and his colleagues are investigating a promising new antibody-drug candidate called trastuzumab deruxtecan, or T-DXd, for certain groups of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback